A reliable computational workflow for the selection of optimal screening libraries by Yocheved Gilad et al.
Gilad et al. J Cheminform  (2015) 7:61 
DOI 10.1186/s13321-015-0108-0
RESEARCH ARTICLE
A reliable computational workflow 
for the selection of optimal screening libraries
Yocheved Gilad1, Katalin Nadassy2 and Hanoch Senderowitz1*
Abstract 
Background: The experimental screening of compound collections is a common starting point in many drug discov-
ery projects. Successes of such screening campaigns critically depend on the quality of the screened library. Many 
libraries are currently available from different vendors yet the selection of the optimal screening library for a specific 
project is challenging. We have devised a novel workflow for the rational selection of project-specific screening 
libraries.
Results: The workflow accepts as input a set of virtual candidate libraries and applies the following steps to each 
library: (1) data curation; (2) assessment of ADME/T profile; (3) assessment of the number of promiscuous binders/
frequent HTS hitters; (4) assessment of internal diversity; (5) assessment of similarity to known active compound(s) 
(optional); (6) assessment of similarity to in-house or otherwise accessible compound collections (optional). For 
ADME/T profiling, Lipinski’s and Veber’s rule-based filters were implemented and a new blood brain barrier permea-
tion model was developed and validated (85 and 74 % success rate for training set and test set, respectively). Diversity 
and similarity descriptors which demonstrated best performances in terms of their ability to select either diverse or 
focused sets of compounds from three databases (Drug Bank, CMC and CHEMBL) were identified and used for diver-
sity and similarity assessments. The workflow was used to analyze nine common screening libraries available from six 
vendors. The results of this analysis are reported for each library providing an assessment of its quality. Furthermore, 
a consensus approach was developed to combine the results of these analyses into a single score for selecting the 
optimal library under different scenarios.
Conclusions: We have devised and tested a new workflow for the rational selection of screening libraries under 
different scenarios. The current workflow was implemented using the Pipeline Pilot software yet due to the usage of 
generic components, it can be easily adapted and reproduced by computational groups interested in rational selec-
tion of screening libraries. Furthermore, the workflow could be readily modified to include additional components. 
This workflow has been routinely used in our laboratory for the selection of libraries in multiple projects and consist-
ently selects libraries which are well balanced across multiple parameters.
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Background
The experimental screening of compound collections is 
a widely used starting point in the search for new bio-
logically active compounds. Many screening libraries 
are currently available either in the public domain or 
from commercial vendors making an exhaustive screen-
ing impossible [1, 2]. Thus, it is important to develop 
rational strategies for the selection of the optimal screen-
ing library and chemoinformatic approaches can be used 
for this purpose.
Many factors should be considered while selecting an 
optimal screening library. Some (e.g., price, compounds 
availability, time for shipment, and vendor reliability) 
are vendor-dependent and will not be further discussed. 
Other factors could be computationally analyzed based 
on compounds structures. Such an analysis requires 
data curation since wrong structures are likely to lead to 
a faulty analysis. Indeed, available databases have been 
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shown to include multiple flawed structures (up to 10 %) 
[3–7].
First, libraries should be selected based on the planned 
screening campaign. Screening campaigns could be 
largely divided into two categories, namely, focused (or 
biased) and unbiased. If the structure of the biologi-
cal target is known a focused screening library could be 
designed, for example, through docking simulations. 
Similarly, if active compounds are known, ligand based 
methods could be used to select a screening library 
which includes additional compounds similar to them. 
Similarity could be assessed in several ways including: 
(1) pharmacophore-based which is particularly useful 
for identifying compounds with the same chemical fea-
tures as the active compounds yet with new chemotypes 
or chemical scaffolds [8, 9], (2) fingerprints-based and 
(3) substructure-based. However, focusing the screen-
ing library entirely on active compounds might be prob-
lematic in particular when only few, structurally similar 
active compounds are known or when the identity of the 
biological target is unknown (see below). In such cases, 
maintaining diversity within the screening library may 
identify compounds with new scaffolds or compounds 
acting through different mechanisms.
Diversity is especially important when neither the 
structure of the biological target nor the structures of 
its ligands are known and more so if the precise identity 
of the target is unknown. Such cases require screening 
at the functional or phenotype levels and based on the 
similar property principle [10], are likely to benefit from 
biologically testing a diverse set of compounds. Chemi-
cal diversity is typically assessed using pairwise distances 
between library members in a pre-defined descriptors 
space. Multiple descriptors and distance metrics were 
evaluated for their ability to select diverse subsets from 
parent databases. In particular, two-dimensional (2D) 
fingerprints coupled with the Tanimoto coefficient as the 
distance metric were shown to give good results in mul-
tiple cases [11].
Aside from diversity/similarity considerations, other 
factors should be considered. In particular, absorp-
tion, distribution, metabolism, excretion, and toxicity 
(ADME/T) profiles are important for both hit identifi-
cation and lead optimization [12–15]. Hence evaluating 
ADME/T properties (e.g., adherence to Lipinski’s “rule of 
five” [16] or Veber’s rules [17], oral bio-availability, lack of 
toxic group [18] or other properties calculated by means 
of QSAR models [19–21]) across a screening library is a 
useful criterion for library selection. In addition, promis-
cuous binders or frequent HTS hitters should be avoided 
[22] since these are likely to turn up as false positive upon 
hit validation. Such consideration formed the basis for 
several compounds removal filters [23–26].
Finally, an additional consideration for library selec-
tion could be invoked, namely, similarity to in-house 
compound collections. Assessing the overlap between 
a library candidate for purchasing and in-house avail-
able compound collections is critical to avoid duplicates 
and to assess whether the candidate and available librar-
ies cover similar parts of the chemistry space. Depend-
ing on the specific project, a library may be selected to 
fill “holes” in chemistry space or to improve coverage of 
regions already occupied by the in-house library.
This work focuses on the selection of whole libraries 
for phenotypic screening. Our interest in this challenge 
emerged from our involvement in multiple screening 
projects targeting rare diseases such as Leukoencepha-
lopathy with vanishing white matter (VWM disease) 
[27], the neurodegenerative amyotrophic lateral sclero-
sis (ALS) disease [28], and cystic fibrosis (CF) [29]. In all 
of these projects the selection of a screening library was 
hampered by lack of information on the identity or the 
structure of the biological target or on active compounds.
Some chemoinformatic tools required to address the 
issues described above have been described in the lit-
erature. Similarly, multiple descriptors have been evalu-
ated for their ability to select either diverse or focused 
sets of compounds [30–33]. However, these tools were 
not combined into a unified workflow for the ranking 
and subsequent selection of screening libraries based 
on multiple criteria. With this in mind we have devel-
oped such a workflow consisting of the following steps: 
(1) data curation; (2) ADME/T profiling; (3) assessment 
of promiscuous binders/frequent HTS hitters; (4) assess-
ment of internal diversity; (5) assessment of similarity to 
known reference compounds; (6) assessment of similar-
ity to in-house available compound collections. For step 
(2) we have included as library characteristic adherence 
to Lipinski’s and Veber’s rules and as an important com-
ponent of the ADME/T profiling, we have developed 
and validated a new blood brain barrier permeation 
model. This model was developed due to our involve-
ment in multiple projects requiring blood brain barrier 
permeating compounds. Other models could be simi-
larly developed based on the specific requirements of 
other projects. For step (3) we have implemented a filter 
based on substructures of known promiscuous binders/
frequent HTS hitters. For step (4), 25 two-dimensional 
descriptor sets (fingerprints) were evaluated for their 
ability to select diverse subsets of compounds from 
within the Drug Bank, CMC or CHEMBL databases. 
Diversity was estimated as coverage of target (Drug Bank, 
CHEMBL) or indication (CMC) spaces. The best “diver-
sity descriptors” were incorporated into the workflow. 
For step (5) the same descriptors were evaluated for their 
ability to identify known active compounds based on 
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their similarity to a reference active compound from the 
three databases. The best “similarity descriptors” were 
incorporated into the workflow. These similarity descrip-
tors were also utilized in step (6). Library ranking was 
based on a simple consensus approach considering all the 
above parameters. As a proof of concept, this workflow 
was used to evaluate nine common libraries available 
from six vendors and to select a library with the most 
balanced profile in terms of all these parameters.
Results
An overview of the workflow is presented in Fig. 1.
LogBB model
The performances of the best logBB QSAR model on 
training and test compounds are presented in Additional 
file 1: Figure S1a, b, respectively and are overall satisfac-
tory (R2train = 0.66; R2test = 0.67). The QSAR equation takes 
the form:
where AlogP98 is an atom-type based log partition coef-
ficient, DPSA1 is the difference between the positive 
log BB = 1.2827+ 0.17977× AlogP98− 0.0033777
× DSPA1− 0.18676×Num_H_Acceptors
+ 0.1557× SsssN − 0.022135× �4.6743− SssCH2�
solvent-accessible area and the negative one, Num_H_
Acceptors is the number of hydrogen bond acceptors and 
SsssN and SssCH2 are specific electrotopological state 
indices.
Transferring the quantitative predictions into qualita-
tive ones (i.e., logBB ≥ 0, BBB permeable; logBB < 0, BBB 
impermeable) leads to success rates of 85 and 74  % for 
training set and test set, respectively. Positively charged, 
negatively charged and neutral compounds are predicted 
by the model with similar accuracies making it applicable 
to multiple charge states. Finally, the results of Y-scram-
bling (R2train: 0.07 ± 0.07; R2test: 0.18 ± 0.28) demonstrate 
the lack of chance correlation.
Selection of diversity descriptors
Results obtained from the diversity analysis are pre-
sented in Fig.  2a–c and in Additional file  1: Tables S1–
S3 for subsets selected from Drug Bank, CMC, and 
CHEMBL, respectively. The results demonstrate that: 
(1) in all three cases, performance differences between 
the different fingerprints are mostly apparent for inter-
mediate subset sizes and (2) for the three databases, the 
ECFP_2 fingerprint performed best in terms of its abil-
ity to select small subsets which cover large parts of the 
targets/indications space. The performances of ECFP_2 
Fig. 1 Outline of the workflow
Page 4 of 17Gilad et al. J Cheminform  (2015) 7:61 
were closely followed by those of ECFP_4 and ECFP_6. 
Additional fingerprints (e.g., MDL keys, and the 2D phar-
macophoric fingerprints PHRFC_2) also performed well 
while the poorest results were obtained with some of the 
other 2D pharmacophoric fingerprints (e.g. PHPFP_4 
and PHPFC_4) and as expected with random selection. 
Due to the high similarity between ECFP_2, ECFP_4, and 
ECFP_6 we chose to incorporate into the workflow three 
well-performing yet more diverse fingerprints (ECFP_2, 
MDL keys, and PHRFC_2) and evaluate library diversity 
using a consensus approach.
Selection of similarity descriptors
Enrichment curves obtained for the similarity analysis 
are presented in Fig. 3a–f for active compounds selected 
from the Drug Bank, CMC and CHEMBL, respec-
tively. Based on this analysis four fingerprints, ECFP_4, 
ECFP_6, MDL, and PHFP_3, were identified as best for 
similarity selection and incorporated into the work-
flow. Interestingly two of these fingerprints (ECFP_4, 
ECFP_6) were identified as best for the diversity analysis 
as well. Other non-pharmacophoric fingerprints (ECFP, 
FCFP and MDL) also performed well while four out of 
six 4-point pharmacophoric fingerprints (PHPFP_4, 
PHRFP_4, PHPFC_4 and PHRFC_4) were found to be 
the least successful.
Application to external libraries
The resulting workflow was used to rank nine screen-
ing libraries obtained from six known vendors with the 
aim of selecting the best library under different sce-
narios as listed below. These input libraries are listed 
in Table 1 together with average values of several key 
descriptors.
Fig. 2 Assessment of “diversity descriptors”. Each graph presents the % of target (Drug Bank, CHEMBL) or indications (CMC) coverage as a function 
of the subset size for five of the 25 fingerprints evaluated in this work (see Additional file 1: Tables S1–S3 for details for all fingerprints). The five plots 
in each graph correspond to fingerprints covering the entire ranking range. a Selections made from Drug Bank. b Selections made from CMC. c 
Selections made from CHEMBL
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All nine libraries were downloaded as SDF files and 
were subjected to the complete workflow. The results are 
presented in Tables 2, 3, 4, 5, 6, 7, 8, 9 and 10.
Data curation
The results of data curation are presented in Table 2 and 
demonstrate that all libraries evaluated in this work are 
Fig. 3 Enrichment curves obtained from the similarity analysis for six of the 25 fingerprints considered in this work (see Additional file 1: Tables 
S4–S9 for details on all fingerprints). a–f refer, respectively to Carbinoxamine, a ligand of the Histamine H1 receptor (CMC), fluocinolone aceto-
nide, a ligand of the glucocorticiod receptor (CMC), lymecycline, an antibiotic drug (Drug Bank), haloperidol, an antipsychotic drug (Drug Bank), 
CHEMBL488890, a ligand of the Melanin-concentrating hormone receptor 1 and CHEMBL14759 a ligand of the human immunodeficiency virus 
type 1 protease as the reference (known active) compounds. For fingerprints in which the Tanimoto coefficient levels off before covering 100 % of 
the target there is no way to differentiate the compounds from one another hence these fingerprints are displayed as straight lines from the point 
where the coefficients levels off
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of high quality and only negligible compounds fractions 
(0–3 %) were filtered by the data curation step
ADME/T profiling
ADME/T profiling results are presented in Table  3. 
Overall, most compounds obey Lipinski’s and Veber’s 
rules yet for several libraries the percentage of com-
pounds violating these rules is not negligible (Plati-
num Collection 6.4, 7.4  %, respectively, and Prestwick 
Chemical Library® 7.9, 13.5  %, respectively). Between 
39 and 66  % of compounds are predicted not to cross 
the blood brain barrier with the Maybridge screening 
collection presenting the largest percentage of com-
pounds predicted to be BBB permeating (60.7 %). This 
is closely followed by compounds from the pharma-
cological diversity set and the DIVERSet™-EXP. Not 
unexpectedly, there is no clear correlation between 
the percent of molecules which fail the Lipinski/
Veber filters and those which are predicted to be BBB 
impermeable.
Promiscuous binders
Some of the libraries have non-negligible fraction of their 
compounds classified as promiscuous binders based on 
HTS and PAINS filtration (12 % for Prestwick Chemical 
Library® and 5 % for the Sigma and Maybridge Screen-
ing Collections). This number is negligible for all other 
libraries (see Table 4).
Table 1 List of evaluated libraries










ASINEX Elite libraries 70,114 385.01 2.19 4.22 1.09 4.54
ASINEX Platinum collection 113,962 425.81 3.50 4.72 1.32 6.74
Chembridge DIVERSet™-CL 50,000 347.71 1.81 3.60 1.21 4.96
Chembridge DIVERSet™-EXP 50,000 321.82 2.64 3.35 1.02 4.10
Enamine Drug-like set 20,160 345.07 2.62 3.94 0.93 4.68
Enamine Pharmacological diversity set 10,240 360.80 3.02 3.92 1.02 5.22
Maybridge Screening collection 54,318 332.64 3.30 3.73 0.96 4.38
Prestwick Prestwick Chemical Library® 1280 344.16 1.43 4.36 1.83 5.07
Sigma MSII full library 10,000 312.98 2.51 3.54 1.16 3.90
Table 2 Library quality analysis
a The percent of molecules removed as a result of data curation
Library In-organic (%) Duplicates (%) Mixtures (%) Bad valance (%) Total removed (%)a
Elite libraries 0.0 0.0 0.0 0.0 0.0
Platinum collection 0.0 0.0 0.0 0.0 0.0
DIVERSet™-CL 0.0 0.0 0.0 0.0 0.0
DIVERSet™-EXP 0.0 0.0 0.2 0.0 0.2
Drug-like set 0.0 0.0 1.1 0.0 1.1
Pharmacological diversity set 0.0 0.0 0.9 0.0 0.9
Maybridge screening collection 0.0 0.1 0.1 0.0 0.0
Prestwick Chemical Library® 0.6 0.1 2.4 0.0 3.1
MSII full library 0.0 0.0 0.2 0.0 0.2
Table 3 ADME/T profiling
Library Fail Lipinski (%) Fail Veber (%) LogBB < 0 (%)
Elite libraries 0.0 0.0 65.7
Platinum collection 6.4 7.4 48.0
DIVERSet™-CL 0.0 0.1 61.7
DIVERSet™-EXP 0.0 0.0 41.7










MSII full library 0.2 0.8 49.1
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Internal diversity
Table 5 presents the averaged pairwise Tanimoto coeffi-
cients calculated for the three selected diversity descrip-
tors for all libraries considered in this work. Lower 
numbers (i.e., lower similarities) correspond to higher 
internal diversities. Based on this analysis the Prestwick 
Chemical Library® is the most internally diverse while 
the Elite Library is the least diverse.
Table  6 ranks the different libraries based on the 
ADME/T, promiscuity and internal diversity criteria 
as well as based on their consensus. Clearly different 
libraries rank differently when evaluated according to 
different criteria. The data in Table  6 indicate that: (1) 
based on ADME/T profiling the best screening library is 
DIVERSet™-EXP, (2) based on the promiscuity criterion 
the best screening library is the Platinum collection, (3) 
based on internal diversity the best screening library is 
Prestwick Chemical Library® and (4) when considering 
all three criteria with equal weights the best screening 
library is DIVERSet™-EXP dataset. Several libraries (e.g., 
DIVERSet™-EXP and Platinum collection) having equal 
ranks. Selecting between these equally ranked librar-
ies will therefore require additional considerations, e.g., 
price or time to delivery.
Similarity to known active compounds
Thus far, the analysis was only based on the character-
istics of library compounds and is therefore suitable for 
selecting screening libraries for unbiased screening. 
However, when additional information is available, e.g., 
knowledge of active compounds, it can be used to favora-
bly bias the selection.
With this in mind, each library was evaluated with 
respect to its similarity to known (arbitrary selected) 
active compound(s). For this purpose we selected two 
sets of compounds: (1) a set of benzothiazole deriva-
tives with known anti-hyperglycemic activity previously 
identified by us (Fig.  4a) [34]. These compounds were 
selected to exemplify the usage of a rigorously built and 
validated pharmacophore model in the selection pro-
cedure. These compounds were therefore only used for 
Table 4 Promiscuous binders






Pharmacological diversity set 1.8
Maybridge screening collection 4.6
Prestwick Chemical Library® 11.8
MSII full library 5.0
Table 5 Internal diversity
Library Mean similarity
ECFP_2 MDL PHRFC_2
Elite libraries 0.229 0.561 0.068
Platinum collection 0.216 0.519 0.098
DIVERSet™-CL 0.199 0.515 0.053
DIVERSet™-EXP 0.199 0.405 0.074
Drug-like set 0.163 0.415 0.067
Pharmacological diversity set 0.208 0.447 0.084
Maybridge screening collection 0.168 0.355 0.073
Prestwick Chemical Library® 0.138 0.346 0.036
MSII Full library 0.157 0.107 0.069
Table 6 Library ranking based on ADME/T, promiscuous binders, diversity, and the consensus of the three
a The “Total Rank” column provides the sum of the “ADME/T”, promiscuity and “Diversity” columns and in parenthesis, the final rank of each library
b The ADME/T, promiscuous binders and diversity ranking were obtained from Tables 3, 4 and 5, respectively, using the same consensus approach as described in 
the text. In the case of ADME/T, consensus was taken over the Lipinski, Veber and logBB criteria. In the case of diversity, consensus was taken over the three selected 
diversity descriptors (ECFP_2, MDL, PHRFC_2)
Library ADME/Tb Promiscuous bindersb Diversityb Total ranka
Elite libraries 4 2 7 13 (4)
Platinum collection 6 1 8 15 (5)
DIVERSet™-CL 3 5 7 15 (5)
DIVERSet™-EXP 1 4 5 10 (1)
Drug-like set 3 6 3 12 (3)
Pharmacological diversity set 2 3 6 11 (2)
Maybridge screening collection 3 7 3 13 (4)
Prestwick Chemical Library® 7 9 1 17 (6)
MSII full library 5 8 2 15 (5)
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pharmacophore-based similarity (Fig.  4b) and were not 
used for library ranking; (2) Vertex’s Kalydeco which 
was recently approved by the FDA for the treatment of 
Cystic Fibrosis [35] (Fig.  5a). This compound was used 
as a proof of concept to exemplify the usage of a single 
compound-based pharmacophore. In order to analyze 
the similarity of the libraries to this compound all three 
approaches were used (pharmacophore-based (Fig.  5b), 
fingerprints-based using the best similarity descriptors, 
ECFP_4, ECFP_6, MDL and PHFP_3 fingerprints and 
substructure-based (Fig. 5c).
The results of these analyses are presented in 
Table  7. The library with the largest number of com-
pounds completely (i.e., with no omission of pharma-
cophoric features) matching the benzothiazole derived 
pharmacophore is the Platinum collection. All librar-
ies (except Elite Libraries) feature more than ten phar-
macophore-matching compounds. This is especially 
interesting in light of the large number of features 
included in this model (eight features). Not surpris-
ingly, the number of matches increased when allow-
ing for the omission of three features. In the case of 
Kalydeco, different similarity metrics led to differ-
ent results with DIVERSet™-CL, Platinum collection, 
and DIVERSet™-EXP providing the largest number of 
matches using pharmacophore (either with or without 
feature omission), fingerprint or substructure-based 
similarity, respectively. For all libraries, pharmacoph-
ore-based similarity with the omission of two features 
yielded the largest number of similar compounds yet, 
these numbers drastically decreased when requiring 
complete matching, probably due to the large number 
of feature in this pharmacophore model (seven fea-
tures). Figure  6 presents some of the best matches to 
Kalydeco obtained from the different libraries.
Results obtained with each similarity method could 
be individually used as selection criteria. Alternatively, 
a consensus approach could be used (see Table 8). Based 
on this consensus, the library with the largest number of 
compounds similar to Kalydeco is DIVERSet™-EXP.
The ranking of the libraries based on molecular similar-
ity can be combined with the results presented in Table 6 
into a single consensus score. The new rank is provided 
in Table  9 and demonstrates that upon introducing the 
similarity to a known active drug criteria (Kalydeco), the 
highest ranking library is now DIVERSet™-EXP.
Finally all libraries were compared to the 
DIVERSet™-CL library (arbitrarily selected to represent 
an in house compound collection) using ECFP_4 which 
was previously identified as the best similarity finger-
print and a 0.7 Tanimoto coefficient cutoff. The results 
of this analysis are presented in Table  10 and indicate 
that none of the other libraries contain a large number 
of compounds similar to those in DIVERSet™-CL. Nev-
ertheless, these numbers were used to rank the different 
libraries in terms to their “overlap” with DIVERSet™-CL 
(lower overlapping libraries allocated higher ranks) and 
this ranking was combined with the previous rankings 
into a single consensus score for library selection. The 
new ranking of the eight libraries is presented in the last 
column of Table 10 and identifies the DIVERSet™-EXP as 
the best library.
Fig. 4 a Active (1–3) and inactive (4–5) benzothiazole derivatives 
used to build and validate a pharmacophore model. b Active com-
pound 3 fitted to the pharmacophore model. Green, cyan, and orange 
colors represent H-bond acceptor, hydrophobic and ring-aromatic 
features, respectively
Fig. 5 a Kalydeco structure. b Kalydeco fitted to its pharmacophore 
model. Purple, green, cyan, and blue colors represent H-bond donor, 
H-bond acceptor, hydrophobic-aromatic and hydrophobic-aliphatic 
features, respectively. c Kalydeco’s substructure used for substructure-
based similarity analysis, where x represents one of the following 
atoms: nitrogen, oxygen, sulfur, aliphatic carbon or aromatic carbon
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Discussion
This work presents a new workflow for the rational selec-
tion of libraries for biological screening. The development 
of this workflow was motivated by three main factors: 
(1) the screening of compound collections is a widely 
used starting point in many drug discovery projects. (2) 
Multiple compound collections from different vendors 
are currently available presenting practitioners in the field 
with the challenge of how to select the best one for a given 
project. This is particularly true when one wishes to select 
a complete library rather than to cherry pick a set of com-
pounds from multiple libraries. (3) A unified workflow 
Table 7 Number of compounds found to be similar to a known active compound(s)
a In brackets is the size of the library following data curation
b For pharmacophore-based similarity, two fitting procedures were performed either requiring a fit of all pharmacophoric features or allowing the omission of three/
two features from the benzothiazole derivatives and Kalydeco pharmacophore models, respectively
Librarya Benzothiazole derivatives Kalydeco
Pharmacophore-basedb Pharmacophore-basedb Substructure-based Fingerprint-based
All features Omitting three All features Omitting two ECFP_4 ECFP_6 MDL PHFP_3
Elite libraries (70,111) 3 5419 2 2402 0 0 0 200 0
Platinum collection 
(113,961)
414 4942 0 1685 7 0 0 2076 0
DIVERSet™-CL (50,000) 22 32,547 19 8719 0 0 0 125 0
DIVERSet™-EXP (49,888) 61 30,203 4 8014 30 0 0 530 0
Drug-Like Set (19,932) 116 15,067 4 3687 6 0 0 82 0
Pharmacological diversity 
set (10,144)
151 8250 4 2687 5 0 0 81 0
Maybridge screening  
collection (54,174)
112 10,110 2 2530 3 1 0 514 0
Prestwick Chemical  
Library® (1240)
14 663 1 249 0 0 0 11 0
MSII full library (9980) 30 5822 0 1533 1 0 0 291 0
Fig. 6 Compounds from the DIVERSet™-EXP and the Maybridge screening collection libraries which were identified as similar to the active com-
pound Kalydeco using the three similarity methods, pharmacophore-based, fingerprint-based and substructure-based
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for the ranking of multiple candidate screening libraries 
based on multiple criteria is unavailable.
The main focus of the workflow is the selection of com-
plete libraries for unbiased screening, namely screen-
ing which is not biased by knowledge of the structure of 
the biological target or of compounds known to interact 
with it. This screening often uses a phenotypic biological 
end point. This scenario is typical in projects where this 
knowledge is lacking (i.e., projects targeting new biological 
targets or new indications) or in projects where previous 
efforts utilizing this knowledge did not lead to active com-
pounds. Nevertheless, in its current implementation the 
workflow can take advantage of known active compounds 
and use them as part of the library selection scheme.
Table 10 Similarity to ‘In-House’ library and final rankings
a The “Total rank” column provides the sum of all rankings, namely, ADME/T profiling, promiscuous binders, internal diversity, similarity to an active compound 
(Kalydeco) and similarity to an in-house reference library (DIVERSet™-CL)
Library Similar molecules (%) Library comparison ranking Total ranka
Elite libraries 0.1 2 7 (4)
Platinum collection 0.0 1 5 (3)
DIVERSet™-EXP 0.1 2 3 (1)
Drug-like set 0.1 2 4 (2)
Pharmacological diversity set 0.0 1 4 (2)
Maybridge screening collection 0.1 2 5 (3)
Prestwick Chemical Library® 0.0 1 8 (5)
MSII full library 0.1 2 8 (5)
Table 8 Library ranking based on similarity to Kalydeco
a The “Total rank” column provides the sum of all rankings and in parenthesis, the final rank of each library
Library Substructure-based Pharmacophore-based Fingerprint-based Total 
ranka
Elite libraries 7 6 4 17 (6)
Platinum collection 2 7 1 10 (2)
DIVERSet™-CL 7 1 5 13 (4)
DIVERSet™-EXP 1 2 2 5 (1)
Drug-like set 3 3 6 12 (3)
Pharmacological diversity set 4 4 7 15 (5)
Maybridge screening collection 5 5 2 12 (3)
Prestwick Chemical Library® 7 8 8 23 (7)
MSII full library 6 8 3 17 (6)
Table 9 Ranking based on ADME/T, promiscuous binders, diversity and similarity to Kalydeco
a The “Total rank” column provides the sum of all rankings and in parenthesis, the final rank of each library
Library ADME/T ranking Promiscuous binders Diversity ranking Similarity ranking Total 
ranka
Elite libraries 4 2 7 6 19 (5)
Platinum collection 6 1 8 2 17 (4)
DIVERSet™-CL 3 5 7 4 19 (5)
DIVERSet™-EXP 1 4 5 1 11 (1)
Drug-like set 3 6 3 3 15 (2)
Pharmacological diversity set 2 3 6 5 16 (3)
Maybridge screening col-
lection
3 7 3 3 16 (3)
Prestwick Chemical Library® 7 9 1 7 24 (7)
MSII full library 5 8 2 6 21 (6)
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The workflow accepts as input virtual representations 
of a set of screening libraries, typically as SD files. Such 
files could be downloaded from the sites of most ven-
dors. In the present work we have retrieved, analyzed 
and ranked for selection nine screening libraries from six 
different vendors for a total of ~380,000 compounds (see 
Table 1). Data curation suggests that all libraries are well 
curated with only a small number of duplicates (Table 2). 
These usually result from different salts which were 
stripped as part of the data curation process. Similarly, 
all libraries have overall a favorable ADME/T profiles 
as reflected by adherence to Lipinski’s and Veber’s rules 
and lack of promiscuous binders and frequent HTS hit-
ters. These observations are in accord with the tendency 
of vendors to produce drug-like libraries. Interestingly, 
the Prestwick Chemical Library® which consists of FDA 
approved drugs has the largest fraction of compounds 
failing Lipinski’s and Veber’s rules (7.9 and 13.5 %, respec-
tively). These findings are in line with the notion that not 
all drugs obey the Lipinski/Veber rules [36, 37].
ADME/T profiling was augmented by blood brain per-
meation predictions. For this purpose we developed and 
validated a logBB QSAR model using the genetic func-
tion approximation algorithm. The performances of the 
model are in line with previously reported logBB mod-
els [21, 38, 39]. For the purpose of evaluating screening 
libraries the quantitative model predictions were con-
verted into permeable/impermeable categories leading to 
a success rate of  ~80  %. We view this categorization as 
viable since at this stage we are only interested in the per-
centage of library compounds predicted to be BBB per-
meable/impermeable and not in the precise logBB values. 
Based on this model, between 34 and 61  % of libraries 
compounds are predicted to be blood brain barrier per-
meating with the Maybridge screening collection pre-
senting the largest proportion (61  %). Thus, this library 
may be the most appropriate for the discovery of drugs 
targeting the central nervous system [40].
The internal diversity of compounds collections is espe-
cially important in unbiased, phenotypic screening since 
it increases the probability of identifying active hits. Sev-
eral studies for evaluating diversity descriptors have been 
reported in the past [11, 33, 41] and it was not our inten-
tion to repeat them. Rather, we wished to identify, from 
within the set of fingerprints available to us those that 
not only perform best in target space but also could be 
used to identify diverse compounds in indication space. 
Again this is highly relevant for screening where the bio-
logical end point is based on phenotypic changes rather 
than on binding to a specific target. The best results were 
obtained by the ECFP_2, ECFP_4, and ECFP_6 finger-
prints. These descriptors are highly related and only dif-
fer in the maximal distance (in terms of bond lengths) 
used for their derivation (two, four, and six for ECFP_2, 
ECFP_4, and ECFP_6, respectively). Thus ECFP_6 con-
tains all features within ECFP_4 and ECFP_2. Still, we 
find it interesting, that the smallest fingerprint (ECFP_2) 
performed as well as (and marginally better) than the 
larger fingerprints. The ECFP results are expected to be 
library dependent since for libraries that contain a lot of 
analogues the smaller fingerprints (i.e., ECFP_2) would 
show more similarity compared to the larger fingerprint 
(i.e., ECFP_6) which would also consider the “decora-
tions” on the scaffold.
Similarity to active compounds (if such are known) 
could be used to bias the selection of the screen-
ing library. The amount of biasing is user defined and 
depends on the number of active compounds used for 
searching the libraries and on the similarity threshold. 
Introducing some biasing into the library selection pro-
cess does not interfere with the main purpose of this 
workflow, namely, the selection of libraries for pheno-
typic screening but rather increases the probability of 
identifying active hits. As for diversity, our purpose was 
not to challenge the literature consensus on the perfor-
mance of fingerprint in similarity searching [42]. Rather 
our findings that the ECFP_4 fingerprint performed best 
also in the limited similarity searches we have performed 
in this work strengthen this consensus and extends it to 
the field of biological indications. Other descriptors that 
performed well for similarity searches are ECFP_6, MDL, 
and PHFP_3.
In this work similarity to known active compounds 
was assessed by three metrics, namely, fingerprint-bases 
(as discussed above), pharmacophore-based and sub-
structure-based. In the case of Kalydeco, the usage of 
multiple similarity metrics allowed for some instructive 
comparisons. While most of the best similarity descrip-
tors (ECFP_4, ECFP_6 and PHFP_3) provided only 
few matches to Kalydeco, MDL fingerprints provided 
multiple matches from most libraries. With respect to 
pharmacophore-based similarity, only few matches were 
identified using the pharmacophore model with complete 
fitting. This result is not surprising due to the large num-
ber of pharmacophoric features in this model (seven). 
Feature-rich pharmacophores are useful for identifying 
compounds with high selectivity profiles. Allowing for 
the omission of two pharmacophoric features greatly 
increased the number of matches and in fact this meas-
ure provided the largest number of compounds similar to 
Kalydeco. Pharmacophore-based similarity can identify 
hits with structural diversity larger than those identified 
with substructure-based or fingerprint-based similarity 
searches. Finally, substructure-based similarity identified 
slightly larger numbers of matches than those identified 
by the complete matching pharmacophore model.
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Overall we found no correlation between the library 
size and the number of similar compounds obtained 
from it. We further found no correlation between the 
number of compounds obtained using different similar-
ity metrics. This last observation supports our decision 
to rank libraries based on their similarity to known active 
compounds using a consensus approach.
When in-house compound collections are available, 
they could also be used to bias library selection via two 
opposite strategies. (1) Select a library which is the most 
dissimilar from the in-house library in order to avoid 
compound redundancy and to improve coverage of 
chemistry space. (2) Select a library which is the most 
similar to the in-house library if the latter has favorable 
properties. In this work we found no overlap between the 
DIVERSet™-CL library (arbitrarily selected to represent 
an in-house compound collection) and any of the other 
libraries considered in this work. This finding however is 
largely dependent on the reference library.
One criterion which was not used for library ranking is 
library size. This is because high throughput screening is 
to a large extent “a game of numbers”. Resources afford-
ing, it is better to screen more compounds. This how-
ever, should be balanced against the additional resources 
required. Of note is that despite its size the Platinum col-
lection did not come up as the highest ranking library 
under any of the scenarios except while considering the 
promiscuous binders ranking only.
Ranking of the nine libraries considered in this study 
in terms of the above-discussed criteria is provided in 
Tables 6, 8, 9, and 10. This information by itself may be 
useful for researchers interested in library screening. 
ADME/T profiling, compound promiscuity and inter-
nal diversity are the only metrics that do not depend on 
arbitrary choices made in this work (i.e., using Kalydeco 
as a reference active compound and DIVERSet™-CL as a 
reference in-house library). Based on these criteria, the 
best library is DIVERSet™-EXP Set which is closely fol-
lowed by Enamine’s Pharmacological diversity and Drug-
like sets. When incorporating the similarity to a known 
active compound criterion the best library is Chem-
bridge’s DIVERSet™-EXP followed by Asinex’s plati-
num collection and when adding the distance from an 
in-house compounds collection the best libraries is still 
Chembridge’s DIVERSet™-EXP followed by Enamine’s 
Drug-like set. Using the different criteria the top ranked 
library in all three cases was Chembridge’s DIVERSet™-
EXP however the second best library varied. Changing 
the active compound or the in-house reference library 
will likely change the results.
An important feature of the current workflow is its flex-
ibility which is manifested in multiple ways: (1) new com-
ponents could be easily added. These could include new 
algorithms for the assessment of diversity and similarity, 
new tools to flag compounds with undesired properties 
and new QSAR models, either for activity prediction or 
for additional ADME/T profiling. (2) The ranking scheme 
could be easily modified either by including/omitting 
new criteria or by allocation different weights to different 
criteria. In this way the workflow can be easily tailored to 
select the best library under different scenarios.
The current workflow was implemented using the Pipe-
line Pilot software yet most of its components are availa-
ble through different resources and consequently it could 
be implemented using alternative tools. In the following 
we provide a short, non-exhaustive list of options. Tools 
for data curation are available through the ChemAxon 
cheminformatics platform [43] which also allows for sim-
ilarity searches. Pharmacophore models could be derived 
and used for database searching using Pharmer [44, 45] 
and PharmaGist [46, 47]. Additional similarity searches 
based on fingerprints, 2D pharmacophoric finger-
prints and the Tanimoto coefficient could be performed 
with RDKit [48] or with the CDK toolkit [49]. Multiple 
descriptors could be calculated with the Dragon program 
[50] and QSAR algorithms could be derived with WEKA 
[51]. Finally, these tools could be combined into a single 
workflow using component integration platforms such as 
KNIME [52].
Conclusions
We have devised a new workflow for the rational selec-
tion of screening libraries under different scenarios. This 
workflow has been routinely used in our laboratory for 
the selection of such libraries in multiple projects and 
consistently selects libraries which are well balanced 
across multiple parameters. We therefore expect this 
workflow to be useful for other laboratories engaged in 
drug discovery projects. The Pipeline Pilot workflow 
could be found in the supporting information. This work-
flow could be easily modified, e.g., by including addi-
tional components.
Methodology
The library selection workflow was created using the 
Pipeline Pilot software version 8.5 [53] (although other 
tools could also be used; see discussion section). The 
Pipeline Pilot implementation is shown in Additional 
file  1: Figure S2 and the workflow is available in Addi-
tional file 2.
Data curation
Data curation includes the removal of duplicates, inor-
ganic molecules, mixtures, and salts, the standardization 
of chemical structures, the determination of protonation 
states at physiological pH (7.4) and the selection of the 
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tautomeric state. In this workflow we selected only a sin-
gle tautomer for each compound in order not to inflate 
the screening libraries. However multiple tautomers 
could be readily added.
ADME/T profiling
Adherence to Lipinski’s and Veber’s Rules
Compounds violating more than one of Lipinski’s criteria 
(H-bond donors  >5, Molecular weight  >500, CLogP  >5, 
H-bond acceptors  >10) or any of Veber’s criteria (rotat-
able bonds  ≤10, and polar surface area  ≤140  Å2 or 
H-bond count ≤12) were flagged and their number was 
used as a criterion for library selection.
Development of a blood brain barrier permeation (logBB) 
QSAR Model
A quantitative logBB model was developed from a data-
base of 152 compounds with known logBB values which 
was assembled from the literature [21, 38, 54]. 70 of these 
compounds are positively charged, 75 are neutral and 
7 are negatively charged. 33 of these compounds were 
identified as outliers using a new, k nearest neighbor-
based outlier removal algorithm and removed [55]. The 
remaining compounds were divided into training and test 
sets (80 and 39 compounds, respectively) [56]. Models 
were generated based on training set compounds using 
the Genetic Function Approximation (GFA) as imple-
mented in the Discovery Studio [57] and the best model 
(based on the lack-of-fit criterion) was validated with the 
test set. To guard against chance correlation, Y-scram-
bling was performed by randomly shuffling the activities 
within the training set and repeating the model genera-
tion and validation steps. This procedure was repeated 
ten times.
The validated model was added to the library selec-
tion workflow and was used to predict the logBB values 
of molecules in the input libraries. Quantitative results 
were transformed into qualitative results by consider-
ing compounds with predicted logBB  ≥  0 as permeat-
ing and compounds with logBB < 0 as non-permeating. 
This information was used as another library selection 
criterion.
Promiscuous Binders
The filtration of promiscuous binders was implemented 
by using the HTS filter available in Pipeline pilot and by 
complementing it with additional substructures based on 
the PAINS filter [23]. A list of all substructures used for 
filtration is given in Additional file 1: Table S10.
Internal diversity
Internal diversity was evaluated using molecular fin-
gerprints to characterize compounds and the Tanimoto 
coefficient to calculate pair-wise distances between them. 
Other similarity coefficients are available but the Tani-
moto coefficient represent a well validated and commonly 
used option [58, 59]. The average distance over all pairs 
was taken to represent the library’s internal diversity. 
Prior to library evaluation, the best “diversity descriptors” 
were selected by evaluating the performances of differ-
ent fingerprints in terms of their ability to select diverse 
subsets from within the Drug Bank [60], the Comprehen-
sive Medicinal Chemistry (CMC) [61] and the CHEMBL 
databases. Diversity was evaluated by the number of dif-
ferent targets/indications covered by the selected subsets. 
This (indirect) diversity measure has its disadvantages as 
similar ligands can bind to different targets or alterna-
tively, structurally diverse ligands may bind to the same 
target. However, we chose this method since this was 
highly applicable to the initial question addressed in this 
work, namely, the selection of compound libraries which 
would produce active hits upon screening. Other meth-
ods are available for evaluating diversity but each would 
have its own limitations and biases.
The Drug Bank database (downloaded on Nov. 2013) 
contains 721 compounds covering 215 different targets. 
In order to improve the compound-target ratio, targets 
with only one compound were removed from the data-
base resulting in a dataset of 597 compounds covering 91 
targets. Data curation and descriptors calculation led to 
the removal of five entries containing more than a sin-
gle compound, five inorganic compounds, three dupli-
cates, and 77 compounds for which descriptors could 
not be calculated (typically since these compounds did 
not include the required number of pharmacophoric fea-
tures) and to a final dataset of 507 compounds covering 
84 targets (see Additional file 1: Table S11).
The CMC database (downloaded on Nov. 2013) con-
tains 9522 pharmaceutical compounds. These were clas-
sified into different indications by manually inspecting all 
database entries (we define indication as a certain symp-
tom which could be treated by the compound rather than 
the binding of the compound to a certain target). Follow-
ing the removal of compounds classified into more than 
one target, the removal of targets with only one or two 
compounds and data curation (removal of 81 entries with 
more than a single molecule, 128 inorganic molecules, 
21 duplicates, and 594 compounds for which descriptors 
could not be calculated), the final dataset contained 4264 
compounds covering 104 different biological indications 
(see Additional file 1: Table S12).
The June 2015 version of the CHEMBL database was 
downloaded and filtered to retain all compounds con-
taining a benzene ring and with MW < 800 Dalton lead-
ing to a dataset with 1,098,971 compounds. This dataset 
was further processed first by removing compounds 
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classified to more than a single target, then by removing 
targets with only one or two compounds and finally by 
subjecting it to data curation. This last stage led to the 
removal of 376 inorganic molecules, 145 duplicates, and 
2408 compounds for which descriptors could not be cal-
culated. The final dataset contained 106,860 compounds 
covering 1207 different targets (see Additional file  1: 
Table S13).
Distributions of key properties of the three filtered 
datasets (molecular weight, AlogP, number of rotatable 
bonds, number of H-bond donors and acceptors) are 
given in Additional file 1: Figures S3–S5.
The curated datasets were subsequently used for 
the selection of the “diversity descriptors”. For this, 26 
subsets covering a range of 20–507 in 20 compounds 
intervals were selected from the Drug Bank data-
set, 22 subsets covering a range of 5000–106,860 were 
selected for the CHEMBL dataset and 43 subsets cov-
ering a range of 100–4264 in 100 compounds intervals 
were selected from the CMC dataset, using 25 2D fin-
gerprints (FCFP_2, FCFP_4, FCFP_6, ECFP_2, ECFP_4, 
ECFP_6, MDL Public keys, PHFP_2, PHFP_3, PHFP_4, 
PHPFP_2, PHPFP_3, PHPFP_4, PHRFP_2, PHRFP_3, 
PHRFP_4, PHFC_2, PHFC_3, PHFC_4, PHPFC_2, 
PHPFC_3, PHPFC_4, PHRFC_2, PHRFC_3, PHRFC_4 
[62, 63], see additional information for a brief descrip-
tion of the fingerprints evaluated in this work) for a 
total of 650, 1075 and 550 subsets for Drug Bank, CMC 
and CHEMBL, respectively. Selections were made using 
the ‘Diverse Molecule’ component as implemented in 
Pipeline Pilot [53]. Each subset was checked for the 
number of different targets (Drug Bank, CHEMBL)/
indications (CMC) it covered and this number was plot-
ted as a function of subset size for the different finger-
prints (Fig. 2). In this graph, higher Y values correspond 
to better “diversity fingerprints”. The best fingerprint 
was taken as that with the highest averaged targets/
indications coverage across all subsets and across the 
three datasets. For comparison we evaluated the per-
formances of random numbers by selecting subsets of 
similar sizes at random.
Similarity to known active compounds
Similarity to known active compounds was evaluated 
using three different approaches, namely, pharmacoph-
ore-based, fingerprint-based, and substructure-based. In 
this work we arbitrarily selected as an active compound 
the Cystic Fibrosis (CF) drug Kalydeco (Fig.  5a) which 
was recently approved by the FDA for the treatment of 
CF patients having the G551D mutation [35]. For phar-
macophore based similarity, we used as another example, 
a series of benzothiazole derivatives with known anti-
hyperglycemic activity [34].
Pharmacophore‑based similarity
Pharmacophore models were derived using the com-
mon feature pharmacophore generation procedure 
as implemented in the Discovery Studio software [57] 
using the following pharmacophoric features: H-bond 
donors and acceptors, positive and negative ionizable 
centers, aromatic rings and hydrophobic centers. Two 
strategies were considered: (1) building a pharmaco-
phore from multiple active and inactive compounds. 
In the present study, this strategy was exemplified by 
using a pharmacophore previously developed by us 
from a series of benzothiazole derivatives with known 
anti-hyperglycemic activity. This pharmacophore was 
developed based on five compounds (three active and 
two inactive) and was shown to accurately distinguish 
between active and inactive compounds in an external 
test set consisting of 32 compounds [34]. (2) Building 
a pharmacophore based on a single active compound. 
In the present study this strategy was exemplified by 
building a pharmacophore from the cystic fibrosis (CF) 
drug Kalydeco (Fig.  5b). No information is available 
about the bioactive conformation of Kalydeco however 
due to its relative rigidity a reasonable pharmacophore 
model could nevertheless be proposed. We note that 
this pharmacophore was not validated and is presented 
only as a proof of concept. In both cases, mapping was 
performed twice either while allowing pharmacoph-
oric features to be omitted (a maximum of two for the 
Kalydeco pharmacophore and three for the benzothia-
zole derivatives pharmacophore) or with no omissions 
allowed.
Fingerprint‑based similarity
As in the case of diversity analysis, prior to library 
evaluation it was necessary to select the best “similar-
ity descriptors”. This was performed by evaluating the 
performances of the same fingerprints in terms of their 
ability to identify from within the Drug Bank, CHEMBL 
and CMC databases active compounds based on their 
similarity to known reference (active) compounds. For 
this purpose, two compounds representing the two larg-
est target classes in Drug Bank (Fluocinolone acetonide 
(DB00591) and Carbinoxamine (DB00748) belonging to 
the Glucocorticiod receptor and Histamine H1 recep-
tor classes, respectively) were selected. Next, all Drug 
Bank compounds were ranked according to their simi-
larity with respect to each reference compound using 
all 25 fingerprints and each ranked list was used for the 
calculation of an enrichment curve. A similar analysis 
was performed on the CMC database using Haloperidol 
(MCMC00000084), and Lymecycline (MCMC00001545) 
representing, respectively, the antipsychotic, and anti-
biotic indications and on the CHEMBL database using 
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CHEMBL488890 and CHEMBL14759 representing, 
respectively, the Melanin-concentrating hormone recep-
tor 1 and Human immunodeficiency virus type 1 pro-
tease. The best “similarity descriptors” were taken to be 
those producing the highest enrichment across all six 
reference compounds from the three databases. Highest 
enrichment was considered as the highest averaged active 
compounds coverage over the entire enrichment curve 
and across all six compounds (Fig. 3). These descriptors 
were introduced into the workflow and their usage was 
exemplified by searching the screening libraries for com-
pounds similar to Kalydeco.
Substructure‑based similarity
A substructure of Kalydeco (Fig. 5c) was generated from 
its structure by removing all substituents and by setting 
the heteroatom in the pyridinone ring to nitrogen, oxy-
gen, sulfur, aliphatic carbon or aromatic carbon. This 
substructure was used for library screening.
Similarity to an ‘In-House’ library
Library comparison was performed by identifying 
compounds in the new library which are similar to 
compounds in an ‘in-house’ library. In this study we 
arbitrarily selected DIVERSet™-CL as the in-house 
library. Similarity was evaluated by calculating Tani-
moto coefficients using the best similarity fingerprints 
identified in Sect.  “Selection of similarity descriptors” 
above. For each new library, the number of compounds 
similar (using a similarity threshold of 0.7) to com-
pounds within the in-house library was calculated and 
this number was used as a criterion for library selec-
tion (lower numbers corresponded to a high library 
rank).
Consensus ranking
Consensus scoring was implemented by first ranking 
each library according to each criterion so that the best 
library gets a score of 1 and the worst, a score of x, x 
being the number of libraries and then by combining the 
individual ranks. The library with the lowest combined 
rank (score) is taken to be the best one.
Application to external libraries
Nine libraries from six different vendors were down-
loaded from the corresponding sites (see Table  1) and 
subjected to the workflow described above. These librar-
ies were analyzed under different scenarios and the best 
library in each case was identified.
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